M. Schuhmacher, M. Mari, Michael P. Tsang, G. Sonnemann
{"title":"环境风险评估","authors":"M. Schuhmacher, M. Mari, Michael P. Tsang, G. Sonnemann","doi":"10.1201/9780203488171.CH4","DOIUrl":null,"url":null,"abstract":"New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.","PeriodicalId":148169,"journal":{"name":"Integrated Life-Cycle and Risk Assessment for Industrial Processes and Products","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2003-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Environmental Risk Assessment\",\"authors\":\"M. Schuhmacher, M. Mari, Michael P. Tsang, G. Sonnemann\",\"doi\":\"10.1201/9780203488171.CH4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.\",\"PeriodicalId\":148169,\"journal\":{\"name\":\"Integrated Life-Cycle and Risk Assessment for Industrial Processes and Products\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrated Life-Cycle and Risk Assessment for Industrial Processes and Products\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1201/9780203488171.CH4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated Life-Cycle and Risk Assessment for Industrial Processes and Products","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1201/9780203488171.CH4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.